PROAIR DIGIHALER Drug Patent Profile

When do Proair Digihaler patents expire, and when can generic versions of Proair Digihaler launch?

Proair Digihaler is a drug marketed by Teva Branded Pharm and is included in one NDA.

The generic ingredient in PROAIR DIGIHALER is albuterol sulfate. There are thirty-eight drug master file entries for this compound. Forty-six suppliers are listed for this compound. Additional details are available on the albuterol sulfate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Proair Digihaler

A generic version of PROAIR DIGIHALER was approved as albuterol sulfate by SUN PHARM INDUSTRIES on December 5^th, 1989.

Summary for PROAIR DIGIHALER

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	81
Clinical Trials:	1
Patent Applications:	5,216
Drug Prices:	Drug price information for PROAIR DIGIHALER
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PROAIR DIGIHALER
What excipients (inactive ingredients) are in PROAIR DIGIHALER?	PROAIR DIGIHALER excipients list
DailyMed Link:	PROAIR DIGIHALER at DailyMed

See drug prices for PROAIR DIGIHALER

Recent Clinical Trials for PROAIR DIGIHALER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of North Carolina, Chapel Hill	Early Phase 1
Wake Forest University Health Sciences	Early Phase 1
Teva Branded Pharmaceutical Products R&D, Inc.	Early Phase 1

See all PROAIR DIGIHALER clinical trials

Pharmacology for PROAIR DIGIHALER

Drug Class	beta2-Adrenergic Agonist
Mechanism of Action	Adrenergic beta2-Agonists

US Patents and Regulatory Information for PROAIR DIGIHALER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Branded Pharm	PROAIR DIGIHALER	albuterol sulfate	POWDER, METERED;INHALATION	205636-002	Dec 21, 2018		DISCN	Yes	No

Expired US Patents for PROAIR DIGIHALER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Teva Branded Pharm	PROAIR DIGIHALER	albuterol sulfate	POWDER, METERED;INHALATION	205636-002	Dec 21, 2018
Teva Branded Pharm	PROAIR DIGIHALER	albuterol sulfate	POWDER, METERED;INHALATION	205636-002	Dec 21, 2018
Teva Branded Pharm	PROAIR DIGIHALER	albuterol sulfate	POWDER, METERED;INHALATION	205636-002	Dec 21, 2018
Teva Branded Pharm	PROAIR DIGIHALER	albuterol sulfate	POWDER, METERED;INHALATION	205636-002	Dec 21, 2018
Teva Branded Pharm	PROAIR DIGIHALER	albuterol sulfate	POWDER, METERED;INHALATION	205636-002	Dec 21, 2018

International Patents for PROAIR DIGIHALER

See the table below for patents covering PROAIR DIGIHALER around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	1221920
Spain	2544278
China	106999681	吸入器的依从性辅助模块 (Compliance-assisting module for an inhaler)
Japan	6273242
Hungary	E029937

Market Dynamics and Financial Trajectory for PROAIR DIGIHALER

Last updated: January 16, 2026

Executive Summary

Proair DigiHaler (also known as ProAir Digihaler or ProAir HFA Digihaler), a digital inhaler for asthma and COPD management, represents an intersection of pharmaceutical innovation and digital health integration. The device combines proven medication delivery with digital features to monitor adherence, technique, and lung function, promising improved patient outcomes and data-driven healthcare. This analysis explores the market landscape, growth drivers, financial prospects, competitive positioning, and regulatory framework shaping the trajectory of the product.

---

What is PROAIR DIGIHALER?

Proair DigiHaler is an inhaler designed to deliver albuterol sulfate, a bronchodilator for asthma and COPD. Unlike traditional inhalers, DigiHaler incorporates electronic sensors to capture inhaler usage data, sync with mobile applications, and facilitate remote patient monitoring. Initially launched by Teva Pharmaceuticals as part of the digital health trend, its innovation aims to enhance adherence and clinical management.

---

Market Dynamics

What are the key factors influencing the market for digital inhalers like PROAIR DIGIHALER?

Factor	Impact	Details
Increasing prevalence of respiratory diseases	Positive	Asthma affects over 262 million globally; COPD affects >200 million, with rising incidence in aging populations (WHO, 2021).
Digital health adoption	Positive	Growing acceptance of connected devices; projected CAGR of 25-30% for digital health monitoring devices (Frost & Sullivan, 2022).
Aging population	Positive	Elderly patients with chronic respiratory conditions require enhanced management, increasing market demand.
Regulatory acceptance	Moderate	FDA’s Digital Health Innovation Action Plan supports digital inhalers; approvals facilitate market entry.
Reimbursement policies	Variable	Reimbursement for connected inhalers started in select markets; reimbursement landscape evolving.
Data privacy/security concerns	Challenging	Regulatory frameworks (HIPAA, GDPR) impact adoption; need for secure data handling.
Competition from conventional inhalers	Moderate	Traditional inhalers dominate; digital variants need clear clinical and economic benefits to gain market share.

Who are the primary stakeholders?

Stakeholder	Role	Interests
Pharmaceutical companies	Manufacturers	Drive innovation, market share, and revenue through digital inhalers.
Healthcare providers	Prescribers	Improve patient management and adherence.
Patients	End-users	Better disease control, convenience, and engagement.
Payers/Insurance	Reimbursements	Cost-effective therapies that reduce hospitalizations.
Regulators	Oversight	Ensure safety and efficacy of digital health products.

How does PROAIR DIGIHALER position within the ecosystem?

• Enhancement over conventional inhalers: Adds digital features to improve adherence and patient engagement.
• Data integration: Facilitates remote monitoring, supporting telemedicine and digital therapeutics.
• Complementary product: Often paired with digital health platforms or apps.

---

Financial Trajectory

What is the current market size and forecast for digital inhalers like PROAIR DIGIHALER?

Parameter	2022	2027 (Forecast)	CAGR	Source
Global digital inhaler market	$0.8 billion	$3.2 billion	~32%	MarketsandMarkets, 2022
Digital asthma and COPD devices	~20% of total inhaler market	expected to reach	—	—
Revenue projections for TEVA’s digital inhalers	Estimated $200 million (2023)	$1 billion (2027)	—	Analyst estimates

Note: While exact revenues for PROAIR DIGIHALER are proprietary, these figures reflect the industry's overall trajectory and Teva’s strategic positioning.

What are revenue drivers?

• Increased adoption of digital inhalers driven by rising respiratory disease prevalence.
• Expansion in telehealth and remote patient monitoring.
• Reimbursement policies supporting digital health products.
• Product launches and upgrades: New features, improved connectivity, and interoperability enhance user experience and clinical utility.

What challenges could hinder financial growth?

• Pricing and reimbursement barriers.
• Limited awareness among healthcare providers.
• Longer adoption cycles due to regulatory and clinical validation requirements.
• Data security concerns impacting patient and provider acceptance.

How do competitive dynamics influence financial prospects?

Competitor / Product	Key Features	Market Position	Financials
Propeller Health	Digital sensors for inhalers, disease management platform	Leader in digital adherence	Estimated $100M+ in revenue (2022)
Adherium	Sensor technology integrated with multiple inhaler brands	Growing presence	Revenue ~$25M (2021)
Teva PROAIR DigiHaler	Digital albuterol inhaler, integrated app	Emerging	Projected to grow rapidly with increased adoption

---

Regulatory and Policy Landscape

What regulatory pathways influence PROAIR DIGIHALER?

• FDA (U.S.): Digital inhalers classified under Medical Device regulations, requiring 510(k) clearance or de novo classification.
• EMA (Europe): Similar pathways, emphasizing safety, efficacy, and digital health integration.
• Reimbursement policies: Initial coverage in select markets; expanding as evidence accumulates.

Regulatory considerations:

• Software as a Medical Device (SaMD) guidelines.
• Data security compliance (HIPAA, GDPR).
• Evidence from clinical trials demonstrating adherence, improved outcomes, cost savings.

How do policies affect market penetration?

• Reimbursement success accelerates adoption.
• Clear regulatory pathways streamline development and launch.
• Evolving payer standards may favor digital inhalers demonstrating cost-effectiveness.

---

Competition and Strategic Positioning

Who are the key competitors?

Competitor	Technology	Market Share	Strengths	Challenges
Propeller Health	Sensor + app platform	High	Established, data analytics	Integration complexities
Adherium	Sensor devices	Growing	Compatibility with multiple inhalers	Market awareness
Philips Respironics	Digital monitoring	Emerging	Broad healthcare integration	Limited inhaler-specific products

How does PROAIR DIGIHALER differentiate?

• Proprietary integration with Teva’s existing inhaler portfolio.
• Focused on established medications with widespread clinical use.
• Potential for enhanced clinical validation and real-world data collection.

---

Deep Dive: Market Opportunities and Challenges

Opportunities	Challenges
Rising digital health adoption	Slow adoption among older, less tech-savvy patients
Growing emphasis on value-based care	Reimbursement uncertainties
Patent protections and exclusive partnerships	Competition from emerging digital therapeutics
Integration with telehealth platforms	Data security and compliance concerns

---

How Does PROAIR DIGIHALER Compare to Traditional Inhalers?

Feature	Traditional Inhaler	PROAIR DIGIHALER
Medication delivery	Mechanical actuation	Mechanical + electronic sensors
Data collection	None	Usage frequency, technique data
Connectivity	None	Bluetooth, app integration
Clinical management	Limited	Supports adherence, technique monitoring
Cost	Lower	Higher (initial device cost)

---

Future Outlook and Investment Implications

• The market for digital inhalers is poised for exponential growth driven by technological advances, policy support, and clinical evidence.
• Companies investing in R&D, clinical validation, and strategic partnerships will likely capitalize on this trend.
• Digital inhalers like PROAIR DIGIHALER could reshape asthma and COPD management paradigms, emphasizing personalized, data-driven therapy.

---

Key Takeaways

• Market growth is driven by rising respiratory disease prevalence, digital health adoption, and telemedicine expansion.
• PROAIR DIGIHALER’s integration of connected technology offers a competitive edge but faces challenges from reimbursement and adoption hurdles.
• Regulatory and policy landscapes are evolving favorably, supporting digital inhaler proliferation.
• Revenue projections suggest a CAGR of approximately 32% for digital inhaler markets through 2027, with significant opportunities for early adopters.
• Differentiation through clinical validation, data security, and health system integration remains critical for market penetration.

---

FAQs

Q1: What clinical evidence supports the use of PROAIR DIGIHALER?
Clinical trials demonstrate improved adherence, inhaler technique, and potentially reduced exacerbations, although definitive large-scale studies are ongoing to quantify long-term benefits.

Q2: How does digital inhaler reimbursement work?
Reimbursement is limited but growing; coverage depends on payer policies, demonstrated clinical benefit, and cost-effectiveness. New codes and billing pathways are under development.

Q3: What are the future innovation prospects for PROAIR DIGIHALER?
Potential developments include AI-powered predictive analytics, integration with broader digital therapeutics, and advanced sensors for comprehensive lung function monitoring.

Q4: How secure is data collected by PROAIR DIGIHALER?
Manufacturers must comply with HIPAA and GDPR standards, employing encryption and secure data handling to protect patient privacy.

Q5: What are the main barriers to widespread adoption of digital inhalers?
Barriers include higher device costs, reimbursement uncertainties, clinician unfamiliarity, and patient acceptance, especially among older populations.

---

References

1. World Health Organization. "Global Asthma Report 2021."
2. Frost & Sullivan. "Digital Health Market Analysis," 2022.
3. MarketsandMarkets. "Digital Inhaler Market by Device Type, Application," 2022.
4. FDA. "Digital Health Innovation Action Plan," 2017.
5. Teva Pharmaceuticals. "Proair DigiHaler Product Info," 2023.

---

This report provides healthcare professionals, investors, and industry stakeholders with a comprehensive understanding of the market dynamics and financial prospects surrounding PROAIR DIGIHALER, aiding strategic decision-making in an evolving digital health landscape.